Kymera Therapeutics Inc

NASDAQ:KYMR   3:59:50 PM EDT
59.06
+0.91 (+1.56%)
Earnings Announcements

Kymera Therapeutics Announces Positive Interim Results From Single Ascending Dose Phase 1 Trial Of KT-474 Demonstrating Degrader Proof-Of-Mechanism

Published: 06/28/2021 12:10 GMT
Kymera Therapeutics Inc (KYMR) - Kymera Therapeutics Announces Positive Interim Results From Single Ascending Dose Phase 1 Trial of Kt-474 Demonstrating Degrader Proof-of-mechanism.
Kymera Therapeutics Announces Positive Interim Results From Single Ascending Dose Phase 1 Trial of Kt-474 Demonstrating Degrader Proof-of-mechanism.
Kymera Therapeutics Inc - Kt-474 Has Achieved and Exceeded Phase 1 Target Degradation of 85% Within Sad Portion of Phase 1 Trial Dosed to Date.
Kymera Therapeutics Inc - After Single Dose Administration, Degradation Was Maintained for at Least Six Days at All Dose Levels.
Kymera - FDA Has Lifted Partial Clinical Hold on Multiple Ascending Dose Portion of Phase 1 Trial and Kymera Plans to Initiate Repeat Dosing in July.
Kymera Therapeutics Inc - No Treatment-related Adverse Events Have Been Observed to Date.
Revenue is expected to be $18.81 Million
Adjusted EPS is expected to be -$0.26

Next Quarter Revenue Guidance is expected to be $19.29 Million
Next Quarter EPS Guidance is expected to be -$0.21

More details on our Analysts Page.